Endocrine Abstracts

Castrate Resistant Prostate Cancer (CRPC) is the inevitable outcome of hormone treatment for advanced disease. Although no longer dependent on high levels of androgens, the androgen receptor (AR) remains active and there is evidence that other nuclear receptors (NRs) can drive CRPC progression and/or therapy resistance. NRs share a repertoire of essential coregulators: proteins possessing the ability to aid or repress NR action and have been proposed as a potential mechanism f...

Prostate cancer (PCa) is driven by the androgen receptor (AR) signalling axis and begins with prostatic intraepithelial neoplasia (PIN), progressing to invasive adenocarcinoma and eventually metastatic disease. It is treated with androgen deprivation therapies, to which, in late-stage disease, tumours often become resistant and proliferation occurs in a low androgen environment. Mutation of the PTEN tumour suppressor gene is found in approximately 30% of primary human prostate...

Androgens initially drive prostate tumour growth. Although in advanced disease there is no longer dependence on circulating androgens, the androgen receptor (AR) remains a key driver of this lethal stage thus new ways to inhibit its activity are required. MicroRNAs play vital roles in prostate cancer (PCa) development, progression and metastasis. Previous studies have examined microRNAs dysregulated in PCa, and also identified androgen-regulated microRNAs. We approached microR...

Background: Bile acids (BAs) are end-products of cholesterol catabolism, which act as signalling molecules to regulate glucose, lipid and energy metabolism. BAs activate several receptors including the ligand sensitive transcription factor Farnesoid X receptor (FXR) and the membrane G-protein coupled receptor, TGR5. Besides the organs physiologically in contact with BAs, like the gut and liver, BA-receptors are also expressed in cholesterol-rich steroidogenic tissues, such as ...